NASDAQ:AKTX Akari Therapeutics (AKTX) Stock Price, News & Analysis $6.18 +0.36 (+6.10%) As of 02:18 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Akari Therapeutics Stock (NASDAQ:AKTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Akari Therapeutics alerts:Sign Up Key Stats Today's Range$5.86▼$6.5950-Day Range$3.54▼$10.4452-Week Range$3.25▼$56.80Volume10,578 shsAverage Volume24,089 shsMarket Capitalization$7.04 millionP/E RatioN/ADividend YieldN/APrice Target$89.00Consensus RatingHold Company Overview Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders. Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease. In addition, the company is advancing coversin, a small‐protein C5 inhibitor with potential applications in ophthalmology and hematology. These programs leverage Akari’s proprietary platform chemistry to achieve high specificity and subcutaneous dosing convenience. Headquartered in London, United Kingdom, with research and development operations in the United States, Akari Therapeutics was founded to translate cutting-edge complement science into first-in-class medicines. The company is led by an experienced management team with deep expertise in immunology, drug development and regulatory affairs, and it collaborates with academic institutions and patient organizations to support global clinical studies and future commercialization efforts. AI Generated. May Contain Errors. Read More Akari Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreAKTX MarketRank™: Akari Therapeutics scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingAkari Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAkari Therapeutics has a consensus price target of $89.00, representing about 1,329.7% upside from its current price of $6.23.Amount of Analyst CoverageAkari Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Akari Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioAkari Therapeutics has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.84% of the float of Akari Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkari Therapeutics has a short interest ratio ("days to cover") of 0.32, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akari Therapeutics has recently increased by 151.67%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAkari Therapeutics does not currently pay a dividend.Dividend GrowthAkari Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Akari Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Akari Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Akari Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders30.70% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions5.06% of the stock of Akari Therapeutics is held by institutions.Read more about Akari Therapeutics' insider trading history. Receive AKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKTX Stock News HeadlinesAkari Therapeutics (NASDAQ:AKTX) Stock Price Passes Below 200 Day Moving Average - Should You Sell?May 5 at 4:27 AM | americanbankingnews.comAkari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC PayloadApril 27, 2026 | globenewswire.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.May 7 at 1:00 AM | Weiss Ratings (Ad)Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant TumorsApril 21, 2026 | globenewswire.comMaxim Sees High Risk Profile for Akari Therapeutics, plc (AKTX) Amid Capital NeedsApril 20, 2026 | finance.yahoo.comAkari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA SplicingApril 20, 2026 | globenewswire.comAkari Therapeutics downgraded to Hold from Buy at MaximApril 10, 2026 | finance.yahoo.comAkari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDCApril 9, 2026 | globenewswire.comSee More Headlines AKTX Stock Analysis - Frequently Asked Questions How have AKTX shares performed this year? Akari Therapeutics' stock was trading at $11.56 on January 1st, 2026. Since then, AKTX shares have decreased by 46.2% and is now trading at $6.2250. How were Akari Therapeutics' earnings last quarter? Akari Therapeutics PLC (NASDAQ:AKTX) posted its earnings results on Monday, March, 30th. The biopharmaceutical company reported ($2.68) EPS for the quarter, missing the consensus estimate of ($0.03) by $2.65. When did Akari Therapeutics' stock split? Akari Therapeutics's stock reverse split on Thursday, August 17th 2023.The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Akari Therapeutics? Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Akari Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akari Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), Meta Platforms (META) and GE Aerospace (GE). Company Calendar Last Earnings3/30/2026Today5/07/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 AKTX's financial health is in the Red zone, according to TradeSmith. AKTX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AKTX CIK1541157 Webwww.akaritx.com Phone442080040261Fax646-843-9352Employees9Year Founded2014Price Target and Rating Average Price Target for Akari Therapeutics$89.00 High Price Target$200.00 Low Price Target$27.00 Potential Upside/Downside+1,341.3%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.30 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.34% Return on Assets-35.46% Debt Debt-to-Equity RatioN/A Current Ratio0.44 Quick Ratio0.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$24.75 per share Price / Book0.25Miscellaneous Outstanding Shares1,140,000Free Float793,000Market Cap$7.04 million OptionableNot Optionable Beta0.64 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:AKTX) was last updated on 5/7/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredThe $1.75T "Backdoor" ticker (NOT Starlink)When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...Behind the Markets | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
